HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Bronchial fistula — Clinical Guidelines

Overview

Bronchial fistula refers to an abnormal connection between the bronchial tree and another structure, often complicating conditions like bronchial asthma or chronic obstructive pulmonary disease (COPD). It can lead to recurrent infections and respiratory compromise 4.

Diagnosis

Clinical Presentation: Symptoms may include recurrent pneumonias, hemoptysis, and chronic cough 4.

Imaging: Chest CT with contrast or high-resolution CT is crucial for identifying fistulae 4.

Bronchoscopy: Direct visualization and potential therapeutic intervention 4.

Serum Biomarkers: Elevated levels of chemokines like IL-8 and VEGF may indicate severity in pediatric cases 4.

Management

Antibiotics: For treating infections associated with bronchial fistulae 4.

Antibiotic Therapy Adjuncts: Low-dose erythromycin may improve clinical symptoms and reduce chemokine levels in severe cases 4.

Mucolytic Agents: To address mucociliary dysfunction, enhancing mucous transport 6.

Nutritional Support: Addressing deficiencies in vitamins D and C, which may modulate disease severity 3 2.

Special Populations

Pediatrics: Low-dose erythromycin therapy shows promise in improving symptoms and reducing chemokine levels in severe pediatric bronchial asthma 4.

Nutritional Considerations: Vitamin D and C deficiencies should be addressed, potentially impacting disease severity 3 2.

Key Recommendations

Evaluate Serum Biomarkers: Measure IL-8 and VEGF levels in pediatric patients to assess severity and guide treatment 4 (Evidence: Moderate).

Consider Low-Dose Erythromycin: For severe cases, especially in pediatric patients, to improve clinical symptoms and reduce chemokine levels 4 (Evidence: Moderate).

Address Nutritional Deficiencies: Supplement with vitamins D and C to potentially reduce disease severity 3 2 (Evidence: Moderate).

References

1 Elnaggar RK, Osailan AM, Alghadier M, Elnegamy TE, Morsy WE, Abdrabo MS et al.. Exercise strategies for reversing cardiopulmonary deconditioning in obese children with bronchial asthma: A randomized comparative effectiveness study of constant-load and graded aerobic training. Medicine 2024. link 2 Al-Thagfan SS, Alolayan SO, Ahmed S, Emara MM, Awadallah MF. Impacts of deficiency in vitamin D derivatives on disease severity in adult bronchial asthma patients. Pulmonary pharmacology & therapeutics 2021. link 3 Ginter E, Simko V. Deficiency of vitamin D and vitamin C in the pathogenesis of bronchial asthma. Bratislavske lekarske listy 2016. link 4 Korematsu S, Yamamoto K, Nagakura T, Miyahara H, Okazaki N, Akiyoshi K et al.. The indication and effectiveness of low-dose erythromycin therapy in pediatric patients with bronchial asthma. Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology 2010. link 5 Deng Z. TCM diet therapy for bronchial asthma. Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan 2009. link60067-4) 6 Wanner A. Mucociliary dysfunction in bronchial asthma. Zeitschrift fur Erkrankungen der Atmungsorgane 1981. link

Bronchial fistula